Treatment With Human Wharton's Jelly-Derived Mesenchymal Stem Cells Attenuates Sepsis-Induced Kidney Injury, Liver Injury, and Endothelial Dysfunction
Carregando...
Citações na Scopus
78
Tipo de produção
article
Data de publicação
2016
Editora
ALPHAMED PRESS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
MOREIRA, Roberto de Sousa
CAMARA, Niels O. S.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
STEM CELLS TRANSLATIONAL MEDICINE, v.5, n.8, p.1048-1057, 2016
Resumo
The pathophysiology of sepsis involves complex cytokine and inflammatory mediator networks. Downregulation of endothelial nitric oxide synthase contributes to sepsis-induced endothelial dysfunction. Human Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are known to reduce expression of proinflammatory cytokines and markers of apoptosis. We hypothesized that treatment with WJ-MSCs would protect renal, hepatic, and endothelial function in a cecal ligation and puncture (CLP) model of sepsis in rats. Rats were randomly divided into three groups: sham-operated rats; rats submitted to CLP and left untreated; and rats submitted to CLP and intraperitoneally injected, 6 hours later, with 1 x 10(6) WJ-MSCs. The glomerular filtration rate (GFR) was measured at 6 and 24 hours after CLP or sham surgery. All other studies were conducted at 24 hours after CLP or sham surgery. By 6 hours, GFR had decreased in the CLP rats. At 24 hours, Klotho renal expression significantly decreased. Treatment with WJ-MSCs improved the GFR; improved tubular function; decreased the CD68-positive cell count; decreased the fractional interstitial area; decreased expression of nuclear factor kappa B and of cytokines; increased expression of eNOS, vascular endothelial growth factor, and Klotho; attenuated renal apoptosis; ameliorated hepatic function; increased glycogen deposition in the liver; and improved survival. Sepsis-induced acute kidney injury is a state of Klotho deficiency, which WJ-MSCs can attenuate. Klotho protein expression was higher in WJ-MSCs than in human adipose-derived MSCs. Because WJ-MSCs preserve renal and hepatic function, they might play a protective role in sepsis. SIGNIFICANCE Sepsis is the leading cause of death in intensive care units. Although many different treatments for sepsis have been tested, sepsis-related mortality rates remain high. It was hypothesized in this study that treatment with human Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) would protect renal, hepatic, and endothelial function in a model of sepsis in rats. Treatment with WJ-MSCs improved the glomerular filtration rate, improved tubular function, decreased expression of nuclear factor kappa B and of cytokines, increased expression of eNOS and of Klotho, attenuated renal apoptosis, and improved survival. Sepsis-induced acute kidney injury is a state of Klotho deficiency, which WJ-MSCs can attenuate.
Palavras-chave
Wharton's jelly-derived mesenchymal stem cells, Kidney injury, Liver injury, Endothelium-derived factors, Apoptosis, Interleukins
Referências
- Abraham E, 2007, CRIT CARE MED, V35, P2408, DOI 10.1097/01.CCM.0000282072.56245.91
- Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
- Bagshaw SM, 2007, CLIN J AM SOC NEPHRO, V2, P431, DOI 10.2215/CJN.03681106
- Chang CL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-244
- Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af
- Di Lanni M, 2008, EXP HEMATOL, V36, P309, DOI 10.1016/j.exphem.2007.11.007
- Doi K, 2009, J CLIN INVEST, V119, P2868, DOI 10.1172/JCI39421
- Elman JS, 2014, J INFLAMM-LOND, V11, DOI 10.1186/1476-9255-11-1
- English K, 2009, CLIN EXP IMMUNOL, V156, P149, DOI 10.1111/j.1365-2249.2009.03874.x
- Gonzalez-Rey E, 2009, GUT, V58, P929, DOI 10.1136/gut.2008.168534
- Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943
- Hu MC, 2010, KIDNEY INT, V78, P1240, DOI 10.1038/ki.2010.328
- Jawad Issrah, 2012, J Glob Health, V2, P010404, DOI 10.7189/jogh.02.010404
- Jesmin S, 2012, INFLAMMATION, V35, P484, DOI 10.1007/s10753-011-9337-1
- Jin HJ, 2013, INT J MOL SCI, V14, P17986, DOI 10.3390/ijms140917986
- Jorge L, 2013, J AM SOC NEPHROL, V24
- Kotsaki A, 2012, EXPERT OPIN EMERG DR, V17, P379, DOI 10.1517/14728214.2012.697151
- Kusadasi N, 2013, SHOCK, V40, P352, DOI 10.1097/SHK.0000000000000039
- Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552
- Leelahavanichkul A, 2008, AM J PHYSIOL-RENAL, V295, pF1825, DOI 10.1152/ajprenal.90442.2008
- Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005
- Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6
- Maekawa Y, 2009, ENDOCRINE, V35, P341, DOI 10.1007/s12020-009-9181-3
- Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
- O'Sullivan AW, 2009, J SURG RES, V152, P46, DOI 10.1016/j.jss.2008.04.030
- Oh HJ, 2015, PERITON DIALYSIS INT, V35, P43, DOI 10.3747/pdi.2013.00150
- de Souza ACCP, 2012, AM J PHYSIOL-RENAL, V302, pF1045, DOI 10.1152/ajprenal.00148.2011
- Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203
- Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
- Rochefort GY, 2006, STEM CELLS, V24, P2202, DOI 10.1634/stemcells.2006-0164
- Rodrigues CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029893
- Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105
- Watson N, 2015, CYTOTHERAPY, V17, P18, DOI 10.1016/j.jcyt.2014.08.009
- Xu C, 2014, KIDNEY INT, V85, P72, DOI 10.1038/ki.2013.286
- Xu JG, 2007, AM J PHYSIOL-LUNG C, V293, pL131, DOI 10.1152/ajplung.00431.2006
- Yagi H, 2010, CELL TRANSPLANT, V19, P823, DOI 10.3727/096368910X508942
- Yang HC, 2011, J AM SOC NEPHROL, V22, P2028, DOI 10.1681/ASN.2010090982
- Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393
- Zarbock A, 2014, CURR OPIN CRIT CARE, V20, P588, DOI 10.1097/MCC.0000000000000153
- Zeldich E, 2014, J BIOL CHEM, V289, P24700, DOI 10.1074/jbc.M114.567321